We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AIM ImmunoTech Inc | AMEX:AIM | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.0138 | 3.41% | 0.418 | 0.4198 | 0.3903 | 0.4198 | 48,518 | 23:34:58 |
United States
Securities and Exchange Commission
Washington, DC 20549
Form 8-A/A
(Amendment No. 1)
For Registration of Certain Classes of Securities
Pursuant to Section 12(b) or 12(g) of The
Securities Exchange Act of 1934
AIM IMMUNOTECH INC.
(Exact Name of Registrant as Specified in Charter)
Delaware | 52-0845822 | |
(State
or Other Jurisdiction |
(IRS
Employer |
2117 SW Highway 484, Ocala FL 34473
(Address of principal executive offices) (Zip code)
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which registered | ||
Rights to Purchase Series A | NYSE American | |||
Junior Participating Preferred Stock |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐
Securities Act registration statement or Regulation A offering statement file number to which this form relates: Not Applicable
Securities to be registered pursuant to Section 12(g) of the Act: None.
This Amendment No. 1 to Form 8-A is being filed by AIM ImmunoTech Inc., a Delaware corporation (the “Company”), to update the disclosure in the Company’s Registration Statement on Form 8-A filed with the Securities and Exchange Commission (the “SEC”) on November 14, 2017 (the “Original 8-A”).
ITEM 1. Description of Registrant’s Securities to be Registered.
This amends the Original 8-A relating to the rights (the “Rights”) issued under the Rights Agreement, dated as of November 19, 2002, between the Company and Continental Stock Transfer & Trust Company (“CST”), as the rights agent (the “Original Agreement”), as amended by the Amended and Restated Rights Agreement, dated as of November 2, 2012 (the “2012 Amendment”) and, following American Stock Transfer & Trust Company, LLC (the “Rights Agent”) replacing CST as the rights agent, the Second Amended and Restated Rights Agreement, dated as of November 14, 2017 (the “2017 Amendment” and, together with the Original Agreement and the 2012 Amendment, the “Rights Agreement”). The Rights Agreement, which is intended to enable the Company’s stockholders to realize the long-term value of their investment, was scheduled to expire at the close of business on November 14, 2022.
On November 9, 2022, the Company and the Rights Agent, entered into an amendment to the Rights Agreement (as amended, the “Amended Rights Agreement”), which was unanimously approved by our Board of Directors and which extends the expiration date of the Rights Agreement from November 14, 2022 to February 14, 2023 in order to provide the Board of Director additional time to evaluate whether and for what duration and on what terms to further extend the Amended Rights Agreement in connection with its overall assessment of the Company’s preparedness to respond to threats to corporate control and to ensure that the interests of stockholders are protected.
The Rights and the Rights Agreement are described in the Original 8-A, and such descriptions, as amended hereby, are incorporated by reference herein. The Original Agreement is included as an exhibit to the Company’s Registration Statement on Form 8-A12G (File No. 000-27072) filed with the SEC on November 20, 2002, the 2012 Amendment is included as an exhibit to the Company’s Registration Statement on Form 8-A12G/A (File No. 000-27072) filed with the SEC on November 2, 2012, and the 2017 Amendment is included as an exhibit to the Company’s Registration Statement on Form 8-A12B (File No. 001-27072) filed with the SEC on November 14, 2017. All of the foregoing are incorporated by reference herein.
ITEM 2. Exhibits.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this amendment to the registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
AIM ImmunoTech Inc. | ||
By: | /s/ Thomas K. Equels | |
Thomas K. Equels, | ||
President and Chief | ||
Executive Officer |
Dated as of: November 14, 2022
1 Year AIM ImmunoTech Chart |
1 Month AIM ImmunoTech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions